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Fragile X syndrome is one of the most common genetic causes of mental retardation, yet the mechanisms
controlling expression of the fragile X mental retardation gene FMR1 are poorly understood. To identify
sequences regulating FMR1 transcription, transgenic mouse lines were established using a fusion gene
consisting of an E.coli (3-galactosidase reporter gene (/acZ) linked to a 2.8 kb fragment spanning the 5-region
of FMR1. Five transgenic mouse lines showed lacZ expression in brain, in particular in neurons of the
hippocampus and the granular layer of the cerebellum. Expression of the reporter gene was also detected in
Leydig cells and spermatogonia in the testis, in many epithelia of adult mice, and in the two other steroidogenic
cell types, adrenal cortex cells and ovarian follicle cells. Embryonic tissues which showed strong activity of
the reporter gene included the telencephalon, the genital ridge, and the notochord. This expression pattern
closely resembles the endogenous one, indicating that the 5' FMR1 gene promoter region used in this study
contains most c/s-acting elements regulating FMR1 transcription.
INTRODUCTION
Fragile X syndrome, an X-linked inherited disease and the
most common form of monogenic inherited mental retardation,
is mainly due to a block in the transcription of the fragile X
mental retardation 1 gene (FMR1). Other clinical features of
the fragile X syndrome are postpubertal macroorchidism in
male patients, a longish face, large ears and several symptoms
reminiscent of a connective tissue dysplasia (1). The only
neuroanatomic alteration reported in the brains of affected
patients is a reduction in size of the posterior vermis of the
cerebellum (2). A characteristic feature of the pathogenesis is
the expansion of a CGG-trinucleotide repeat, located upstream
of the translation initiation site in the first exon of FMR1,
and a concomitant cytosine methylation of the CpG island
encompassing the 5'-end of this gene (3,4). It has been
postulated that this erroneous methylation of the putative
promoter region results in the inhibition of transcription of the
FMR1 gene, and that the absence of the FMR1 gene product
leads to the various disease symptoms (3,4). The causative
role of the FMR1 gene for fragile X syndrome has been
confirmed by the description of patients suffering from mental
retardation similar to the fragile X syndrome who carried
deletions in this gene (5-7). Moreover, FMR1 mRNA and
protein were found to be strongly reduced or absent in cells
and tissues derived from fragile X syndrome patients (8-11).
FMR1 consists of 17 exons spanning 38 kb of chromosome
Xq27.3, and the corresponding 4.8 kb transcript is subjected
to alternative splicing resulting in several isoforms of the
protein, including the most abundant 69 kDa isoform (12-14).
The FMR1 gene product is an RNA-binding protein that binds
to various sequences with different affinities. It has been
estimated that about 4% of all mRNAs expressed in the fetal
human brain are bound by the FMR1 protein (15,16). Indeed,
in a mentally retarded male patient with the symptoms of fragile
X syndrome, no CGG-repeat amplification or methylation in
FMR1 was found, however, a point mutation was identified in
FMR1 which inhibited binding of the FMR1 protein to RNA
(17,18). Recently, an animal model for the fragile X syndrome
has been generated by targeted inactivation of the murine
Fmrl gene in embryonic stem cells. The resultant knockout
mice did not express the FMR1 protein and showed increased
testicular weight, learning deficits, and hyperactivity (19).
FMR1 mRNA has been detected by reverse transcriptase-
mediated PCR and Northern blot analyses in a variety of
tissues including fetal brain, liver and pancreas, and adult
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brain, testis and lymphocytes (9,14,20). In situ hybridization
studies localized endogenous human and murine mRNA in
multiple tissues of pre- and postnatal origin. Postnatally FMRl
transcripts were observed in the central nervous system, in
particular in the hippocampus and the cerebellum, and also in
the testis (21,22). Highest FMRl protein expression was
observed in neurons as confirmed by immunostaining (8,11).
More information about the regulation of developmental
and tissue-specific transcription of FMRl will contribute to
our understanding of the pleiotropic phenotype of the fragile
X syndrome and of the molecular mechanisms leading to
transcriptional silencing of FMRl in affected patients. An
established procedure to study the regulation of gene expression
in an organism is the generation of transgenic mouse lines
using a DNA construct consisting of a reporter gene linked to
the relevant regulatory fragment (23). In an attempt to define
cw-acting sequences regulating expression of FMRl, we gener-
ated five transgenic mouse lines by introducing a fusion gene
consisting of the putative 5'-regulatory region of FMRl fused
to lacZ into the mouse genome and analyzed expression of
the reporter gene in developing and adult mice.
RESULTS
Generation of transgenic mice expressing a FMRl/lacZ
fusion gene
The fusion gene FMRl/lacZ contains a fragment from the
upstream region of FMRl linked to the lacZ reporter gene
(Fig. 1). The 2830 bp FMRl sequence includes the 5'-region
of the CpG island and ends 18 bp upstream of the translation
initiation codon. As a major transcription start site of FMRl
has been reported to lie about 320 bp upstream of the translation
initiation codon, approximately 300 bp of 5'-untranslated
sequences are therefore included (12). To direct the reporter
gene product to the nucleus and thereby increase the resolution
of the histological analysis, we used a reporter gene containing
the nuclear localization signal from the large T antigen of
simian virus 40 (SV40) at the N-terminus of p-galactosidase
(24). Injection of the fusion gene into zygote pronuclei resulted
in 43 newborn mice from which six were identified to be
transgenic by Southern blot analysis of tail DNA using a lacZ
probe. The six independent mouse lines and the approximate
copy number of the transgene (in parentheses) within these
lines were: 22 [1-5], 35 [1-5], 38 [5-20], 41 [50-100], 42
[50-100], and 43 [1-5]. Mouse line 38 did not give rise to
transgenic offspring and was excluded from further analysis.
Transgene expression in the central nervous system
The regions of the brain expressing the reporter gene were
identified by overnight whole-mount staining of perfusion-
fixed brains with Bluo-Gal, a substrate for P-galactosidase,
followed by paraffin-embedding and sectioning, or by staining
of frozen sections (23). The expression level was estimated
from staining intensity. Varying concentrations of the reporter
gene product were observed in different parts of the brain
(Fig. 2a -c ; summarized in Table 1). Although the expression
level was variable between the different transgenic mouse
lines, the expression pattern between the five lines was very
similar (Tables 1 and 2). This implies that the observed pattern
was due to intrinsic properties of the FMRl promoter rather
than to positional effects after integration of the transgene.
Both the expression pattern and relative expression level in
tissues were similar or identical between mice of the same
line. The hippocampus and the granular layer of the cerebellum
showed the strongest signals (Fig. 2a, b). In brain slices of
perfused mice, the hippocampus showed intense staining as
early as two hours after incubation, while in other parts of the
brain little or no staining was visible (Fig. 2a). Nevertheless,
overnight staining revealed a lower level of lacZ expression
in other neurons, e.g. in the bulbus olfactorius (Fig. 2c).
Staining was also observed in the retinal bipolar neuronal layer
and in the nervus vagus in the oesophagus (not shown).
Transgene expression in other adult tissues
The lacZ expression was analyzed in testicular and ovarian
tissues (Fig. 3; summarized in Table 2). When visualized by
polarized light, the sensitivity of the lacZ assay is increased
and allows a detailed histological analysis of the expression
pattern (25). Figures 2f,g and 3d,e show the same tissue
specimens in bright field and in dark field with polarized light,
respectively, thus illustrating the increase in sensitivity. In
testis, expression was detected in the interstitial Leydig cells
(Fig. 2f,g). Staining of spermatogonia was strong near the
surface of whole-mount stained testis and in frozen sections
(Table 2), and the seemingly exclusive staining of Leydig cells
in Figure 2g results from better diffusion of (3-galactosidase
substrate in the interstitium compared to diffusion into the
seminiferous tubuli. In female mice, staining was observed in
granulosa cells of the ovarian follicles (Fig. 2e). LacZ activity
was found only in a subgroup of cells at later stages of follicle
development, suggesting that FMRl might be expressed in a
regulated manner during follicle maturation. The oocytes did
not show significant staining. Heart, liver, skeletal and smooth
muscle did not show (J-galactosidase activity (summarized in
Table 2). Staining was observed in a number of epithelia, most
prominently in epithelia lining the organs of the urogenital
system, e.g. urethra, vas deferens and epididymis (Fig. 2d),
and to a lesser degree in the endothelia of the blood vessels
and the epithelia of Bowman's capsule in the kidney. Other
epithelia expressing lacZ were the dermis, the epithelia of hair
follicles, and epithelia in the salivary glands and the trachea.
FMR 1 gene
CpG rich
E1 E2 E17
(CGGhe
Figure 1. Structure of the 5'-end of the FMRl gene and of the FMRl/lacZ
fusion gene injected into mouse oocytes. The restriction sites used for the
construction of the fusion gene are indicated. The narrow part of the construct
is the 5'-fragment of the human FMRl gene. The CpG island, the approximate
transcription start site (arrow), and the CGG-repeat (sphere) are marked, as
well as the nuclear localization signal (N) and the polyadenylation signal
(polyA) from SV40 adjacent to the E.coli lacZ gene.
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Transgene activity during embryonic development
Expression of the FMRlllacL fusion gene was assayed in
transgenic embryos from line 22 at midgestation (Figs 3 and
4; summarized in Table 3). In an 11.5 day old embryo,
expression of the transgene was more widespread than in adult
tissues although not ubiquitous. A strong specific signal was
observed in the notochord, preceding the lacZ expression in
developing intervertebral discs, which contain cells invaginated
from the notochord (Fig. 3c). Expression in cells of the
developing nervous system was also specifically regulated:
Figure 2. Expression of the lacZ reporter gene in tissues of adult transgenic mice. Using Bluo-Gal as chromogenic p-galactosidase substrate, the reaction
product can either be visualized as blue stain in normal light (a, b, c, and 0, or as a bright stain in polarized light (d, e, and g). (a) The frontal brain section in
a 10 week old mouse (line 22) showed intense lacZ activity of the hippocampus after staining for two hours, (b) The cerebellum revealed lacZ expression in
the granular layer, as well as in singular cells in the molecular layer (frozen section, line 41). (c) A frontal section of the bulbus olfactorius showed tissue-
specific lacZ expression in a cone-shaped layer of neurons (frozen section, line 43). (d) The P-galactosidase staining of the epididymis revealed strong lacZ
expression in the epithelium. The sperm cells in the lumen of the epididymal tubules show also some expression of the reporter gene (paraffin embedded section
after whole-mount staining, line 35). (e) In an ovary, lacZ expression was visible in a subgroup of follicle cells, but not in the oocyte. Adjacent follicles in
earlier stages of the ovarian cycle did not show lacZ activity (paraffin embedded section after whole-mount staining, line 41). (f) The same testis section in
bright field (paraffin embedded section after whole-mount staining, line 43). (g) Testis section in polarized light, showing lacZ expression in a group of Leydig cells.
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Table 1. Expression of the lacZ reporter gene in brain tissues of the five transgenic mouse lines
Tissue Line 22 Line 35 Line 41 Line 42 Line 43
Bulbus olfactorius
Caudate putamen
Cerebellum
(granular layer)
Corpus callosum
Choroid plexus
Hippocampus
Neocortex (neurons
of the pyramidal layer)
Retina (neuronal layer)
The estimation of staining intensities was done qualitatively, using four categories: ' + ': single cells visualized with polarized light; ' + + ': majority of all cells
or strong staining of single cells with polarized light, weak staining in bright field; ' + + + ': staining in a tissue in bright field; ' + + + + ': strong staining in
bright field
Table 2. Expression of lacZ reporter gene in different tissues of the five transgenic mouse lines
Tissue Line 22 Line 35 Line 41 Line 42 Line 43
Copy number of the transgene (est.) 1-5
Adrenal gland +
Bone osteoclasts +
Epidermis + +
Epididymis epithelium + + -
Hair follicle + +
Heart muscle —
Intestinal epithelium
Kidney (Bowman's Capsule) +
Liver parenchyma cells —
Lung
Oesophagus -
Oocytes -
Ovary (granulosa cells of follicles) +
Salivary gland + +
Skeletal muscle -
Smooth muscle —
Spleen + +
Testis: Spermatogonia + + + +
Testis: Sperm +
Testis: Leydig cells + +
Testis: Sertoli cells -
Trachea epithelium + +
Urethra epithelium + + -
Uterus
1-5
+
+
50-100
+
50-100 1-5
The estimation of staining intensities was as described in the legend for Table 1
particularly strong expression was detected in the telence-
phalon, whereas other structures, e.g. the neural tube and
the dorsal root ganglia, showed weak or no lacL activity
(Fig. 3a—c). A strong lacL signal was also detected in different
developing organs, e.g., the pericardium and the tongue
(Fig. 3d, e), and in particular in the genital ridge (Fig. 4).
DISCUSSION
After introduction of the FMRl/lacL fusion gene into the
mouse germline, similar expression patterns of the reporter
gene P-galactosidase were found in a number of tissues
of transgenic offspring from five independent founders. We
observed that the tissue-specificity and the level of transgene
expression were regulated similarly to the endogenous gene:
in the brain, the neurons of the hippocampus and the cerebellum
showed the highest p-galactosidase activity. This pattern
resembles transcription of the endogenous gene found in the
brain of human fetuses (21) and adult mice (22). Since the
hippocampus is involved in establishing memory, it is tempting
to speculate that the absence of FMR1 protein in hippocampal
neurons might cause some of the symptoms of mental retard-
ation observed in fragile X syndrome patients. In addition,
strong expression of the transgene occurs in the cerebellum.
Significantly, the only neuroanatomical alteration found in
affected individuals so far is a reduction in size of the posterior
vermis of the cerebellum (2). Different methods were used for
tissue preparation and staining, resulting in a broad range of
detectable staining intensities, and most tissues were analyzed
with several techniques. In particular, polarized light darkfield
imaging increased sensitivity in paraffin sections approximately
10-fold compared to bright field, and paraffin embedding and
frozen sections required sections of different thickness also
affecting staining intensities.
During fetal development, transcription of the human and
mouse gene has been reported to be more widespread than in
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Figure 3. Expression of FMRIAacZ in embryonic tissues at embryonic day 11.5 (mouse line 22). (a) Longitudinal section through the head of a whole mount
stained, paraffin-embedded embryo, photographed in polarized light. Intense staining of the telencephalon is visible, (b) The same section as in (a) shows lacZ
expression in the hindbrain (Hb) adjacent to the fourth ventricle (4th ve). The arrows point to P-galactosidase activity in the roof of the 4th ventricle, (c) Neural
tube, notochord, and spinal ganglia in polarized light (transverse section). No staining is visible in the cells of the neural tube, the neural crest and the spinal
ganglia. LacZ expression is specifically restricted to the notochord (arrow). Some staining is also found in the mesoderm of the somites (lower left), (d) A
longitudinal section of the thorax, showing the developing tongue, the pericardium (Pc), the atrioventricular junction of the heart (Ht), the liver (Li), and the
stomach (St). (e) The same section as in (d) in polarized light shows particularly strong staining in the tongue, the pericardium, and mesenchymal tissues below
the heart and liver.
adult tissues, but the transcription pattern has been controversial
(22,26). In an 11.5 day old embryo, we observed many of the
features described for endogenous Fmrl transcription, most
notably the enhanced expression at the genital ridge and in
the telencephalon revealing tissue specific expression of the
transgene. In addition, lacZ gene product was found in develop-
ing organs such as the pericardium, which do not express the
gene in adults.
In testis, expression of the transgene was found in different
stages of spermatogenesis and in the interstitial Leydig cells.
Expression in spermatogonia was enhanced, but in whole-
mount stained testes the lacL activity seemed to be weak in
those tubuli not directly exposed to the staining solution. This
observation might be explained by a reduced diffusion rate of
the substrate into the tubuli. No transgene expression was
found in Sertoli cells, and no differences in lacL activity have
yet been observed betwen different seminiferous tubuli. We
detected a weak lacL signal in mature sperm of transgenic
mice. However, this signal may have resulted from remnants
of P-galactosidase expressed during earlier stages of spermato-
genesis rather than from transgene expression in mature sperm.
The testicular expression pattern of endogenous Fmrl showed
enhanced gene transcription in the periphery of seminiferous
tubules, which was either located to Sertoli cells (22) or to
spermatogonia (26). Different tubuli showed different levels
of Fmrl transcription (22,26). The FMR1 protein was identified
in human spermatogonia, but not in sperm, by immunostaining
(8). Transcription or expression of the endogenous gene in
interstitial cells was not observed (8,22,26). Fmrl transcription
was found in ovarian follicle cells in one study (22), but this
result was not confirmed in another publication (26). Our
transgenic animals showed lacZ activity in ovarian follicle
cells. In conclusion, the expression of the FMRl/lacZ transgene
is observed in several cell types in genital organs, where the
transcription pattern of the endogenous gene is either a matter
of debate, or has not been observed yet. Enhanced lacZ
expression was found in the three cell types synthesizing
androgens, namely Leydig cells, ovarian follicle cells and
adrenal cortex cells (27). It is tempting to speculate that the
FMR1 protein has a function in steroid synthesis, and that its
absence might affect the function of the peritubular Leydig
cells. The macroorchidism of fragile X syndrome patients
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Figure 4. Expression of the FMRl/lacZ fusion gene in the genital ridge of
the murine embryo at embryonic day 11.5 (line 22). (a) Longitudinal section
in normal light, (b) The same section in polarized light showing strong (3-
galactosidase activity in the cells of the genital ridge.
Table 3. Expression pattern of the reporter gene in embryonic tissue of mouse
line 22
Tissue Line 22
Telencephalon
Diencephalon
Midbrain
Pons + +
Medulla
Thoracic neural tube
Notochord
Genital ridge
Heart
Liver
Otic vesicle
Spinal ganglia
seems to result from an increase in peritubular tissue (28,29),
although in the enlarged testis of the Fmrl null mutant mice
no apparent changes in cell number or size have been detected
(19). It remains to be elucidated, whether the FMR1 protein
plays a physiological role in the Leydig cells as suggested by
the transgene expression. Another discrepancy between the
expression patterns of the transgene and the endogenous Fmrl
was a lack of lacZ signal in the oesophagus epithelium of
adult transgenic mice (11). In summary, these differences
suggest that some regulatory sequences might be missing from
the 2.8 kb 5'-sequence of FMR1 used in our construct. We
also observed that the expression level of the transgene is not
directly related to its copy number, suggesting that our trans-
gene does not contain a locus control region (30). Indeed, the
mouse lines carrying the highest copy number of the transgene
showed relative low expression level. This phenomenon might
result from inactivation of long strands of tandem repeats of
transgenes (31). Additional regulatory elements might be
located in the 9.9 kb first intron of FMR1, which contains the
3' part of the CpG island excluded from the transgene. For
example, enhancer sequences have been identified in the first
and second introns of the gene for the intermediate filament
nestin, directing expression to differentiating muscle cells and
neural precursors, respectively (32). Independent regulatory
elements acting on a CpG-rich promoter have also been
identified in the Thy I gene. Expression of fusion genes in
transgenic mice was more tissue-specific, when sequences
located downstream from the transcriptional initiation site were
included (33). In contrast, the CpG-rich promoter of the rat
calmodulin gene II was active in neurons and testis of transgenic
mice generated with a construct harboring 294 bp of 5'-
upstream sequence plus 68 bp of 5'-untranslated leader
sequence of calmodulin (34,35). Taken together, the similarity
observed between the expression pattern of the transgene and
the endogenous gene in mouse and in human strongly suggests
that not all, but most of the cw-regulatory sequences of
FMR1 are present within our construct. This notion is further
supported by the similar expression patterns between the
independent transgenic mouse lines.
The mechanism(s) which regulate FMR1 transcription are
not yet understood. A patient with the clinical phenotype of
the fragile X syndrome carrying a 1.6 kb deletion upstream
and adjacent to the CGG repeat of FMR1 confirms that these
sequences are essential for the expression of the gene (6). It
is also known that CpG-rich promoters are present in active
chromatin (36), and can be activated by constitutively bound
transcription factors in response to multiple stimuli in a cell-
specific manner in various cell types including neurons (37).
In the case of FMR1, no factors binding to the promoter region
have been described so far. However, several factors were
found, which bind to the CGG-repeat of FMR1, but the
significance of these protein-DNA interactions for FMR1
gene expression remains to be elucidated (38). In preliminary
experiments, we found binding sites for putative transcription
factors in the FMR1 promoter region by gel mobility shift
assays (M.H., unpublished observations). Mutagenesis of these
binding sites will help to identify functional regulatory
sequences in FMRL Further characterization of elements
controlling FMR1 gene expression using transgenic model
systems like the one described here may contribute to the
understanding of the molecular mechanisms of the fragile X
syndrome of mental retardation.
MATERIALS AND METHODS
Cloning of the fusion gene
pNL(Not2X) is a derivative of the pNL plasmid that expresses the E.coli lacZ
gene with a nuclear localization signal of the SV40 large T antigen at the
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N-terminus of the P-galactosidase and an SV40 polyadenylation signal
downstream of the open reading frame (24). The 5.1 kb £coRI-fragment from
the genomic FMRI clone pE5.1 containing 16 CGG-triplets (39; a gift of Dr
D. Nelson, Houston, USA) was blunt ended with Klenow DNA polymerase
and recut with Nhe\, 18 bp upstream of the ATG codon of the FMRI open
reading frame (12). Before ligation with the £coRI-Mid-fragment of FMR1,
pNL(Not2X) was cut with Sph\, blunt ended with Klenow DNA polymerase,
and digested with Xba\ in the pNL(Not2X) polylinker.
Generation and identification of transgenic mice
The fusion gene was excised by Not\ restriction digestion, separated from
vector-derived sequences by agarose gel electrophoresis and purified by DNA
extraction with Prep-A-Gene (Biorad) and filtration through a Millipore filter
(pore size 0.45 nm). The isolated fragment was injected into the pronuclei of
fertilized oocytes of B6C3F1 heterozygote donor mice, which were transferred
into foster mothers. Transgenic animals were identified by Southern blotting
of //mdlll-digested tail DNA using the E.coli lacZ gene as a probe. Transgenic
founder mice were allowed to mate overnight with nontransgenic animals.
Gestational days were counted from the presence of a vaginal plug in the
morning (embryonic day 0.5).
Analysis of lacZ expression
Animals were anesthetized by inhalation of Methoxyfiurane (Metofane, Arovet
AG), and perfused through the left ventricle with PBS containing 5 IU/ml
heparin, followed by 4% PBS-buffered paraformaldehyde (23). Perfusion-
fixed tissues were directly stained for 12-48 h at 37°C in PBS with 5 mM
K3Fe(III)(CN)6, 5 mM I^FefHXCN^, 2 mM MgCl2, 0.02% NP-40, 0.01%
sodium-deoxycholate, and 1 mg/ml Bluo-Gal (Life Technologies; 100 mg/ml
dissolved in dimethylformamide). The stained tissues were postfixed in 4%
PBS-buffered paraformaldehyde, embedded in paraffin, sectioned in 5 urn
sections and counterstained with hematoxylin. Frozen sections were also made
from tissues of perfused animals, which were frozen in isopentan (Fluka).
Sections of 15-20 u.m were mounted on glass slides, fixed for 5 min in 4%
PBS-buffered paraformaldehyde, washed for 5 min in PBS, and stained under
identical conditions as whole tissues (23). After staining the sections were
washed 10 min in PBS, 10 min in water, covered with Crystal Mount
(Biomeda) and analyzed under bright field and polarized light. The embryos
were fixed in PBS containing 0.2% glutaraldehyde, 2 mM MgCl2, 5 mM
EGTA, and 0.02% NP-40, stained, sectioned and analyzed as described above.
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